Nevertheless, the downregulation of ABCA10, a gene that we did not investigate in the current study, has been reported as a prognostic marker associated with immune infiltration in breast cancer (Chu et al., 2022), suggesting that the fate of breast cancer progression and/or drug resistance is not solely dependent on the ABC transporter molecules investigated in the current study. This evidence concerns the gene ABCG2 and breast carcinoma.